Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Sortase A" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Sortase A (EC 3.4.22.70, SrtA, SrtA protein, SrtA sortase) is an enzyme. This enzyme belongs to the peptidase family C60.
Preparation method of antibody-conjugated medicine, antibody-conjugated medicine and applications
ActiveCN107875398AImprove uniformityImprove coupling efficiencyTetrapeptide ingredientsPharmaceutical non-active ingredientsAntibody conjugateMedicine
The invention discloses a preparation method of an antibody-conjugated medicine, the antibody-conjugated medicine and applications. The preparation method comprises the following steps: firstly, underthe catalysis of Sortase A enzyme, leading LPXTG sequence and oligoglycine linker to generate transpeptidation reaction, so that the anti-CD20 monoclonal antibody is connected with a first linker arm; and then leading an azide group linker and alkynyl linker to generate cycloaddition reaction, so that the first linker arm is connected with a second linker arm. The antibody-conjugated medicine isprepared by utilizing an enzyme-chemical method, so that the usage amount of expensive medicines can be reduced, and the cost can be saved. By adopting difunctional small molecules, the steric hindrance of Sortase A enzyme in transpeptidation reaction can be reduced, and the flexibility is good. The conjugation sites and quantity on the antibody medicines can be efficiently controlled, the uniformity is enhanced, and the in-vivo and in-vitro anti-tumor activity can be improved on the basis of keeping the original antibody affinity.
Owner:ZHEJIANG UNIV
Enzyme and method for marking cell membrane surfaces and researching cell-cell interaction
ActiveCN109797194AImprove labeling efficiencyTag implementationMicrobiological testing/measurementTransferasesCell–cell interactionCell membrane
The invention discloses an enzyme and a method for marking cell membrane surfaces and researching cell-cell interaction, and relates to a staphylococcus aureus sortase A mutant evolved by gene engineering. The mutant can realize proximity effect-mediated marking reaction, the cell membrane surfaces not subjected to gene modification can be marked on the basis, and cell-cell interaction can be accurately caught and marked in vivo and in vitro.
Owner:PEKING UNIV
Method for efficiently producing transpeptidase sortase A by using recombinant escherichia coli
InactiveCN105695438AEfficient productionTroubleshoot low expression levelsBacteriaMicroorganism based processesEscherichia coliRecombinant escherichia coli
The invention discloses a method for efficiently producing transpeptidase sortase A by using recombinant escherichia coli, and belongs to the field of gene engineering. Efficient production of the sortase A in the escherichia coli is successfully achieved, the problem of lower expression level of the enzyme reported at present is solved, production is performed in a 7 L fermentation tank, and the yield of the sortase A can reach 295.2 mg / L and is increased by 58.5% than the yield before optimization; the enzyme activity of unit mass of thalli can reach 4845 U / mg and is increased by 52.8% than the activity before optimization. By system optimization of recombinant strain fermentation production conditions, a foundation is laid for subsequent sortase A industrialized production.
Owner:JIANGNAN UNIV
Application of chlorogenic acid serving as inhibitor of Sortase A
InactiveCN105106188AEffective treatmentEffective in treating infectionsAntibacterial agentsOrganic active ingredientsChlorogenic acidStaphylococcus cohnii
The invention discloses new application of chlorogenic acid, particularly relates to application of chlorogenic acid serving as an inhibitor of Sortase A, and the application is characterized in that chlorogenic acid can be directly added and plant extracts taking chlorogenic acid as main components can serve as an additive for treatment of pathogenic bacterial infection. The application of chlorogenic acid serving as the inhibitor of Sortase A, provided by the invention, has the advantages as follows: the activity of Sortase A can be effectively inhibited under the condition that the addition dosage of chlorogenic acid is much lower than the MIC (minimum inhibitory concentration) thereof, therefore the adhesion between Sortase A and extracellular matrix can be inhibited, the infection caused by pathogenic bacteria like staphylococcus aureus can be effectively treated; besides, the action mechanism taking virulence factors as the target is different from that of conventional antibiotics, the drug resistance is not easily produced, the cross tolerance to conventional antibiotics is avoided, and clinical infection caused by drug resistant pathogenic bacteria also can be effectively treated.
Owner:JILIN UNIV
Method for modifying protein by using transpeptidase Sortase A
The invention discloses a method for modifying protein by using transpeptidase Sortase A, and belongs to the field of genetic engineering. According to the present invention, with magnetic beads capable of specifically adsorbing transpeptidase Sortase A,Sortase A is immobilized on the magnetic beads in one step so as to be used to catalyze conjugation and modification reactions of proteins or short peptides;and with the application of the prepared Sortase A conjugated magnetic beads to directly catalyze the transpeptidase conjugation reaction between the short peptide and the short peptide, the transpeptidase conjugation reaction between the protein and the Biotin, the transpeptidase conjugation reaction between the protein and the resin, the transpeptidase conjugation reaction between theshort peptide and the protein, and the like, the Sortase A conjugated magnetic beads can be recycled at least 5 times compared to the free enzyme, and can maintain the yield greater than the catalytic efficiency of free enzyme.
Owner:JIANGNAN UNIV
Combined vaccine for inhibiting and / or preventing type A streptococcal infection
ActiveCN105056223AEffective protectionImproving immunogenicityAntibacterial agentsBacterial antigen ingredientsSortase ASTREPTOCOCCAL INFECTIONS
The present invention discloses a combined vaccine for inhibiting and / or preventing type A streptococcal infection. The present invention provides a composition for inhibiting streptococcus and / or preventing streptococcal infection, and the composition comprise an immunogen. The immunogen is one of the following 1)-4): 1) the immunogen comprises a sortase A and a C5a protease; 2) the immunogen comprises a sortase A solution and a C5a protease solution; 3) the immunogen comprise a fusion protein containing sortase A and a fusion protein containing C5a protease; and 4) the immunogen comprises a junctional complex of sortase A and polysaccharide and a junctional complex of C5a protease and polysaccharide. The specific amino acid sequence of the sortase A is the N-terminal amino acid residues from site No.22 to No.189 of a sequence 2; and the amino acid sequence of the C5a protease is a sequence 4 in the sequence table. The combined vaccine can be applied to prevention and treatment of mucosal system infections caused a variety of Gram-positive bacteria.
Owner:HAIKOU PHARMA FACTORY
Method for refining protein including self-cutting cassette and use thereof
The present invention relates to a self-cleaving fusion protein including a target protein, a peptide consisting of amino acid sequence represented by LPXTG, a domain of Sortase A having cleaving function, and a tag, which are sequentially positioned from the amino terminal; a nucleic acid encoding the same; an expression vector including the nucleic acid of the present invention; and a cell transformed with the expression vector of the present invention. In addition, the present invention relates to a method for refining a target protein including culturing, dissolving, and purifying the transformed cell, and a method for preparing a therapeutic antibody-drug conjugate by using the purifying method.
Owner:ABTLAS CO LTD
Preparation method and application method of double-network hydrogel for three-dimensional cell culture
ActiveCN113444264AInjectableHigh mechanical strengthCell culture supports/coating3D cultureCell adhesionOrganic chemistry
Owner:SOUTHEAST UNIV
Benzofuran compound, preparation method and applications thereof
InactiveCN105330630AEstablish and optimize preparation methodsAntibacterial agentsOrganic chemistryFuranTert-leucine
The present invention provides a benzofuran compound, a preparation method and applications thereof, wherein the structure is represented by a general formula (I-1) or (I-2), R1, R3 and R4 are any one selected from hydrogen, C1-C5 straight or branched chain alkyl, hydroxyl, an aldehyde group, an acetyl group, a carboxyl group, a cyano group, an amino group, a nitro group, fluorine, chlorine, bromine, an amide group, an ester group, an alkoxy group, an aromatic group, and a heteroaromatic group, R2 is any one selected from hydrogen, C1-C5 straight or branched chain alkyl group, a hydroxyl group, an aromatic group, and a heteroaromatic group, and m and n are integers of 0-5. According to the present invention, the Staphylococcus aureus protease Sortase A substrate polypeptide fragment -LPXTG- is adopted as the structural simulation object, the benzofuran structure is adopted as the simulation substrate proline, and the linked amide hydrophobic fragment segment is used to stimulate the substrate leucine residue to design the novel protease Sortase A inhibitor.
Owner:SHANGHAI JIAO TONG UNIV
Novel methods for enzyme mediated polypeptide conjugation
ActiveUS20170292166A1Increase productionDiminishment of any direct or indirect pathological consequencesHybrid immunoglobulinsPharmaceutical non-active ingredientsStaphylococcus aureusOligonucleotide
Herein is reported a method for producing an enzymatic conjugation product of two polypeptides comprising incubating of a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 20, wherein X can be any amino acid residue), a second polypeptide has an oligo-alanine Am (m=2 (SEQ ID NO: 26), or 3 (SEQ ID NO: 27), or 4 (SEQ ID NO: 28), or 5 (SEQ ID NO: 29)) amino acid sequence at its N-terminus, a third polypeptide with sortase activity which is derived from Staphylococcus aureus Sortase A, and recovering the conjugate from the reaction mixture and thereby producing the enzymatic conjugation product of two polypeptides.
Owner:F HOFFMANN LA ROCHE & CO AG
A method for enzymatically synthesizing cyclic peptides
ActiveCN106349336BInhibition interaction propertiesHigh yieldPeptidesFermentationEnzymatic synthesisCyclic peptide
The invention disclsoes a method for synthesizing cyclic peptides through an enzyme method and belongs to the technical field of cyclic peptide synthesis. The method comprises: mixing linear peptides and sortase A at the mol ratio of 25 to 1, and reacting at 37 DEG C to prepare the cyclic peptides. The yield of the cyclic peptides is 70 percent to 93 percent; the method has the advantages of high yield, simple steps and the like and is green and environmentally friendly. The prepared RGD (arginine-glycine-aspartic acid) linear peptides and the cyclic peptides have a property of inhibiting the mutual effect of integrin alphavbeta3 and extracellular matrixes; the prepared AKRHHGYKRKFH linear peptides and cyclic peptides have a property of inhibiting candida albicans, pseudomonas aeruginosa and staphylococcus aureus and have wide application value.
Owner:JIANGNAN UNIV
A method for constructing high-efficiency secretion and expression of transpeptidase sortase A in Escherichia coli
ActiveCN107541482BEfficient productionTroubleshoot low expression levelsBacteriaHydrolasesEscherichia coliSecretion expression
The invention discloses a method for constructing Escherichia coli capable of efficiently secreting and expressing transpeptidase Sortase A, and belongs to the field of gene engineering. According tothe present invention, the efficient secretion and expression of SortaseA in Escherichia coli is successfully achieved, and the problems that the transpeptidase Sortase A cannot be secreted and expressed and the expression level of the transpeptidase Sortase A in cells is low in the existing report are solved; at the shake flask level, the yield of the obtained sortedaseA can achieve 90.2 mg / L, and the extracellular enzyme activity can achieve 34.2 U / mL; and the foundation is established for the subsequent industrial production of SortaseA.
Owner:JIANGNAN UNIV
Application of salvianolic acid a in the preparation of medicines for the treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus
ActiveCN111053764BReduce adhesionReduce invasionAntibacterial agentsOrganic active ingredientsDiseaseStaphyloccocus aureus
The invention discloses the application of salvianolic acid A in the preparation of medicines for treating Staphylococcus aureus infectious diseases. Specifically, the present invention discloses the application of salvianolic acid A in the treatment of Staphylococcus aureus, especially methicillin-resistant Staphylococcus aureus, alone or in combination with antibiotics. The purpose of the present invention is to introduce salvianolic acid into the treatment of Staphylococcus aureus infection, by using salvianolic acid A to inhibit the important virulence factor Sortase A, significantly reduce the pathogenicity of Staphylococcus aureus, and contribute to the body's immune system The removal of germs. The present invention also clarifies the molecular mechanism of salvianolic acid A inhibiting Staphylococcus aureus Sortase A, provides a reliable basis for salvianolic acid A to treat Staphylococcus aureus infection, and provides an important precursor compound for the development of new therapeutic drugs. It lays a certain foundation for the development of similar traditional Chinese medicines. Compared with the treatment with antibiotics, the treatment with salvianolic acid A has the characteristics of no drug resistance and high cure rate.
Owner:JILIN AGRICULTURAL UNIV
An antibody-dolastatin conjugate and its preparation method and application
ActiveCN107936118BImprove uniformityWiden the optionsPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesAntibodies monoclonal
The invention discloses a preparation method for an antibody-monomethyl auristatin E (MMAE) conjugate. The method comprises the following steps: (1) a monoclonal antibody with an LPXTG sequence at each C terminus of an anti-MART-1 protein presentation peptide EAAGIGILTV / HLA-A2 composite, and monomethyl auristatin E or a monomethyl auristatin E derivative with an oligo-glycine joint are provided; (2) under the catalysis of a Sortase A enzyme, the LPXTG sequences and the oligo-glycine joint are subjected to a transpeptidation reaction, and the monoclonal antibody is coupled with and the monomethyl auristatin E or the monomethyl auristatin E derivative with the oligo-glycine joint; and (3) after the reaction is completed, separation purification is performed, and therefore the antibody-monomethyl auristatin E conjugate is obtained. Through site-direct coupling, the method provided by the invention makes per molecule of the antibody have four molecules of the MMAE, has good uniformity, andexhibits good tumor killing capacity in vivo experiments; and compared with current target spots of ADCs (antibody-drug conjugates), CLA12-vcMMAE ADCs expand the selection areas of the current targetspots of the ADCs, demonstrate the view that an intracellular protein can also be taken as the target spot of the ADCs through presentation of MHC (major histocompatibility complex) I molecules.
Owner:ZHEJIANG UNIV
Preparation and application of 2-(4-substituted phenyl)-3-formamide benzofuranene cyanide compound
ActiveCN109574965AStrong inhibitory activityAntibacterial agentsOrganic active ingredientsCyanide compoundFormamide
The invention provides a preparation and application of a 2-(4-substituted phenyl)-3-formamide benzofuranene cyanide compound. The benzofuranene cyanide compound shown in formula I has a structure shown in the following formula I, wherein the definition of all groups is as described in the description. The compound of the invention adopts Sortase A enzyme as an inhibition target and can be used for preparing drugs for treating and preventing staphylococcus aureus infection. (Shown in the description).
Owner:SHANGHAI JIAO TONG UNIV
A fusion protein vaccine that inhibits streptococcal and/or prevents streptococcal infection
ActiveCN106554421BEasy to removeReduce dosageAntibacterial agentsBacterial antigen ingredientsSerotypeTGE VACCINE
The invention discloses a fusion protein vaccine capable of inhibiting Streptococcus and / or preventing Streptococcus infection. With fusion protein obtained through linkage of sortase A and a cholera toxin B subunit through connecting peptide, the Th17 cell activation level is remarkably increased, the effects of preventing pathogenic bacteria from settling and quickly removing the pathogenic bacteria can be realized, and the fusion protein has protecting effects on Group A Streptococcus of different serotypes and has the superiority of high efficiency, broad spectrum and low cost. With the fusion protein, the use amount of immunogen is reduced, the production technology is simplified, and the production cost is reduced. Meanwhile, the vaccine adopts the way of mucosal immunity, has the characteristics of being free of tissue damage, free of local side effects and convenient to use, and is easy to popularize and use.
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
Novel soluble sortase a
ActiveUS20180216091A1Improve enzymatic activityGood water solubilityAntibody mimetics/scaffoldsFermentationAmino acidListeria monocytogenes
Herein is reported a polypeptide comprising the amino acid sequence of SEQ ID NO: 38 as sole Listeria monocytogenes derived polypeptide and its use in conjugating polypeptides.
Owner:F HOFFMANN LA ROCHE & CO AG
Transamidation reaction in deep eutectic solvents
Herein is reported a method for the enzymatic production of a polypeptide comprising the step of incubating i) a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 01, wherein X can be any amino acid residue) or LPXTA (SEQ ID NO: 41, wherein X can be any amino acid residue), ii) a second polypeptide that has i) a glycinyl, an alaninyl, or a cysteinyl compound at its N-terminus, or ii) an oligoglycine, or oligoalanine, or a cysteine amino acid residue followed by one to three glycine or alanine amino acid residues at its N-terminus, or iii) a lysine amino acid residue within its 5 N-terminal amino acid residues, and iii) a third polypeptide with sortase A activity, in a deep eutectic solvent and thereby producing a polypeptide.
Owner:F HOFFMANN LA ROCHE INC
Application of tectorigenin in preparation of Listeria monocytogenes sortase A inhibitor
InactiveCN113398116AFight infectionAntibacterial agentsOrganic active ingredientsBiofilmTherapeutic effect
The invention relates to application of tectorigenin in preparation of a Listeria monocytogenes sortase A inhibitor. SrtA enzyme activity experiments, biofilm experiments and cell invasion experiments prove that tectorigenin can effectively inhibit SrtA catalytic activity and has a certain inhibition effect on the pathogenicity of Listeria monocytogenes; and a mouse listeria monocytogenes systemic infection model treatment experiment proves that tectorigenin has a good treatment effect on infection caused by listeria monocytogenes.
Owner:JILIN UNIV
Methods for enzyme mediated polypeptide conjugation
ActiveUS10190182B2Increase productionDiminishment of any direct or indirect pathological consequencesHybrid immunoglobulinsFermentationStaphylococcusEnzyme binding
Herein is reported a method for producing an enzymatic conjugation product of two polypeptides comprising incubating of a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 20, wherein X can be any amino acid residue), a second polypeptide has an oligo-alanine Am (m=2 (SEQ ID NO: 26), or 3 (SEQ ID NO: 27), or 4 (SEQ ID NO: 28), or 5 (SEQ ID NO: 29)) amino acid sequence at its N-terminus, a third polypeptide with sortase activity which is derived from Staphylococcus aureus Sortase A, and recovering the conjugate from the reaction mixture and thereby producing the enzymatic conjugation product of two polypeptides.
Owner:F HOFFMANN LA ROCHE INC
Method for refining protein including self-cutting cassette and use thereof
Owner:ABTLAS CO LTD
Enzymes and methods for labeling cell membrane surfaces and studying cell-cell interactions
ActiveCN109797194BImprove labeling efficiencyTag implementationMicrobiological testing/measurementTransferasesStaphylococcusStaphyloccocus aureus
The invention discloses an enzyme and a method for marking the surface of cell membrane and studying cell-cell interaction, and relates to a mutant of Staphylococcus aureus sortase A evolved through genetic engineering, which can realize labeling mediated by proximity effect Based on this reaction, the labeling of non-genetically modified cell membrane surfaces can be achieved, and cell-cell interactions can be accurately captured and labeled in vivo and in vitro.
Owner:PEKING UNIV
Soluble Sortase A
ActiveUS11306302B2Improve enzymatic activityGood water solubilityAntibody mimetics/scaffoldsFermentationMicrobiologyListeria monocytogenes
Herein is reported a polypeptide comprising the amino acid sequence of SEQ ID NO: 38 as sole Listeria monocytogenes derived polypeptide and its use in conjugating polypeptides.
Owner:F HOFFMANN LA ROCHE & CO AG
Benzofuran compound and its preparation method and application
InactiveCN105330630BEstablish and optimize preparation methodsAntibacterial agentsOrganic chemistryFuranTert-leucine
The present invention provides a benzofuran compound, a preparation method and applications thereof, wherein the structure is represented by a general formula (I-1) or (I-2), R1, R3 and R4 are any one selected from hydrogen, C1-C5 straight or branched chain alkyl, hydroxyl, an aldehyde group, an acetyl group, a carboxyl group, a cyano group, an amino group, a nitro group, fluorine, chlorine, bromine, an amide group, an ester group, an alkoxy group, an aromatic group, and a heteroaromatic group, R2 is any one selected from hydrogen, C1-C5 straight or branched chain alkyl group, a hydroxyl group, an aromatic group, and a heteroaromatic group, and m and n are integers of 0-5. According to the present invention, the Staphylococcus aureus protease Sortase A substrate polypeptide fragment -LPXTG- is adopted as the structural simulation object, the benzofuran structure is adopted as the simulation substrate proline, and the linked amide hydrophobic fragment segment is used to stimulate the substrate leucine residue to design the novel protease Sortase A inhibitor.
Owner:SHANGHAI JIAOTONG UNIV
A kind of preparation method of antibody-conjugated drug, antibody-conjugated drug and application
ActiveCN107875398BReduce dosageLow costTetrapeptide ingredientsPharmaceutical non-active ingredientsCD20Antiendomysial antibodies
The invention discloses a preparation method of an antibody-conjugated medicine, the antibody-conjugated medicine and applications. The preparation method comprises the following steps: firstly, underthe catalysis of Sortase A enzyme, leading LPXTG sequence and oligoglycine linker to generate transpeptidation reaction, so that the anti-CD20 monoclonal antibody is connected with a first linker arm; and then leading an azide group linker and alkynyl linker to generate cycloaddition reaction, so that the first linker arm is connected with a second linker arm. The antibody-conjugated medicine isprepared by utilizing an enzyme-chemical method, so that the usage amount of expensive medicines can be reduced, and the cost can be saved. By adopting difunctional small molecules, the steric hindrance of Sortase A enzyme in transpeptidation reaction can be reduced, and the flexibility is good. The conjugation sites and quantity on the antibody medicines can be efficiently controlled, the uniformity is enhanced, and the in-vivo and in-vitro anti-tumor activity can be improved on the basis of keeping the original antibody affinity.
Owner:ZHEJIANG UNIV
Production of thioesters using sortase
ActiveUS11162088B2Diminishment of any direct or indirect pathological consequencesReduce developmentPharmaceutical non-active ingredientsFermentationChemical compoundAminoacylation
Herein is reported a method for the enzymatic production of a thioester comprising incubating i) a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 01, wherein X can be any amino acid residue), ii) a second polypeptide that has at its N-terminus a cysteine amino acid residue or is a cysteinyl compound, and iii) a third polypeptide with sortase A activity.
Owner:F HOFFMANN LA ROCHE & CO AG
Application of fraxetin in anti streptococcus agalactiae infection of aquatic animals
InactiveCN111110671ANo drug resistanceNo toxicityAntibacterial agentsOrganic active ingredientsBiotechnologyAquatic animal
The invention discloses application of fraxetin in anti streptococcus agalactiae infection of aquatic animals. The adhesion effect of streptococcus agalactiae can be reduced through inhibiting the activity of sortase A by fraxetin, so as to reduce the pathogenicity of streptococcus agalactiae to aquatic animals. According to the present invention, the infection model of streptococcus agalactiae oftilapia confirms that fraxetin can play a therapeutic role in the infection of streptococcus agalactiae of tilapia. Fraxetin is the main chemical component of the bark of ash trees, has no toxic sideeffects and residues, and can be used as a pharmaceutical preparation and a feed additive for the prevention and treatment of streptococcus agalactiae of aquatic animals.
Owner:YANGTZE RIVER FISHERIES RES INST CHINESE ACAD OF FISHERY SCI
A combination vaccine for inhibiting and/or preventing type a streptococcal infection
ActiveCN105056223BEffective protectionImproving immunogenicityAntibacterial agentsBacterial antigen ingredientsSortase ASTREPTOCOCCAL INFECTIONS
The present invention discloses a combined vaccine for inhibiting and / or preventing type A streptococcal infection. The present invention provides a composition for inhibiting streptococcus and / or preventing streptococcal infection, and the composition comprise an immunogen. The immunogen is one of the following 1)-4): 1) the immunogen comprises a sortase A and a C5a protease; 2) the immunogen comprises a sortase A solution and a C5a protease solution; 3) the immunogen comprise a fusion protein containing sortase A and a fusion protein containing C5a protease; and 4) the immunogen comprises a junctional complex of sortase A and polysaccharide and a junctional complex of C5a protease and polysaccharide. The specific amino acid sequence of the sortase A is the N-terminal amino acid residues from site No.22 to No.189 of a sequence 2; and the amino acid sequence of the C5a protease is a sequence 4 in the sequence table. The combined vaccine can be applied to prevention and treatment of mucosal system infections caused a variety of Gram-positive bacteria.
Owner:HAIKOU PHARMA FACTORY
Preparation method and application method of double network hydrogel for three-dimensional cell culture
ActiveCN113444264BInjectableHigh mechanical strengthCell culture supports/coating3D cultureCell adhesionEngineering
The invention discloses a preparation method and an application method of a double-network hydrogel for three-dimensional cell culture, which belongs to the field of biomedical materials. Firstly, a methacrylated hyaluronic acid grafted with a Sortase A enzyme-specific substrate short peptide is synthesized. (HAMA) conjugate (HAMA‑P), the substrate is enzymatically cross-linked with a certain concentration of Sortase A to obtain an injectable hyaluronic acid single network hydrogel. The method has the advantages of readily available raw materials, mild reaction conditions, short reaction time, and the like. Then, enzymatically and optically double-crosslinked hyaluronic acid-gelatin double network hydrogels were prepared. (GelMA) hydrogel as the second reinforcement network. The double-network hydrogel prepared by the invention provides a suitable scaffold and three-dimensional microenvironment for cell adhesion and growth, and has good application prospects in injectable tissue engineering, 3D printing, and three-dimensional cell culture.
Owner:SOUTHEAST UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com